Thrombosis Research

Article	Citations
Incidence of thrombotic complications in critically ill ICU patients with COVID-19	3251
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy	1549
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis	1208
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management	430
Severe COVID-19 infection associated with endothelial activation	338
Thrombosis risk associated with COVID-19 infection. A scoping review	285
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels	276
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	190
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China	180
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis	170
D-dimer level is associated with the severity of COVID-19	144
Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography	143
Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?	138
Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom	136
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19	121
Severe arterial thrombosis associated with Covid-19 infection	113
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review	104
Estrogen and thrombosis: A bench to bedside review	97
Anticoagulation and bleeding risk in patients with COVID-19	92
Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism	92
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom	91
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19	79
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave	76
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia	73
Pulmonary embolism in hospitalised patients with COVID-19	73

Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome	72
The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?	72
Mechanisms of thrombosis and cardiovascular complications in COVID-19	71
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?	69
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis	69
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients	65
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?	64
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review	55
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19	55
Venous thromboembolism in non-critically ill patients with COVID-19 infection	55
COVID-19 and thrombotic microangiopathies	52
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients	51
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination	48
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study	47
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	46
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19	44
Pulmonary embolism in a young pregnant woman with COVID-19	44
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review	44
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study	44
In vitro hemocompatibility testing of medical devices	44
Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale	43
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies	43
Genetically predicted obesity and risk of deep vein thrombosis	43
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case	42
The gut microbiome and thromboembolism	41
Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis	41
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management	40
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19	38
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study	38
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort	37
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study	37
Pulmonary infarction in acute pulmonary embolism	36
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	36
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action	36
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia	36
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis	35
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study	35
COVID-19 versus HIT hypercoagulability	35
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study	34
Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry	34
Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid	32
Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review	31
Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients	31
Portal vein thrombosis in a patient with COVID-19	31
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy	30
Thrombotic risk in children with COVID-19 infection: A systematic review of the literature	29
Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: A systematic review and dose-response meta-analysis of cohort studies among four million participants	29
Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia	29
COVID-19 and thrombosis: The role of hemodynamics	29
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report	29

Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy	28
Pulmonary embolism: A complication of COVID 19 infection	28
Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study	28
Advances in the management of coagulopathy in acute promyelocytic leukemia	27
Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection	27
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future	26
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19	26
Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal	26
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis	25
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets	25
Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines	25
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system	25
A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients	25
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease	25
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome	24
Novel contributions of neutrophils in the pathogenesis of abdominal aortic aneurysm, the role of neutrophil extracellular traps: A systematic review	24
Management of venous thromboembolism in pregnancy	24
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis	24
Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19	24
Bacterial outer membrane vesicles induce disseminated intravascular coagulation through the caspase-11-gasdermin D pathway	23
The use of prophylaxis in the treatment of rare bleeding disorders	23
The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome	23
Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis	23
Links between thrombosis and inflammation in traumatic brain injury	23
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit	23
Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: A systematic review	23
Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion	22
A perioperative bivalirudin anticoagulation protocol for neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation	22
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases	22
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study	22
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE	22
The domino effect triggered by the tethered ligand of the protease activated receptors	22
COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism?	22
Arterial and venous thrombosis: What's the link? A narrative review	22
A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic	21
The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants	21
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection	21
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases	21
ROTEM diagnostic capacity for measuring fibrinolysis in neonatal sepsis	21
Heavy menstrual bleeding in women on oral anticoagulants	21
The thrombin–inflammation axis in cancer progression	21
Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients	21
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection	21
Pulmonary embolism and deep vein thrombosis: Similar but different	20
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population	20
Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review	20
Recombinant human DNase I for the treatment of cancer-associated thrombosis: A pre-clinical study	20
Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients	20
Role of upfront CT pulmonary angiography at admission in COVID-19 patients	20
Diverse thrombus composition in thrombectomy stroke patients with longer time to recanalization	19
Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects	19
COVID-19 and hypercoagulability in the outpatient setting	19
Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials	19
Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient	19
Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis	19
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine	19
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?	19
Management of high-risk pulmonary embolism in pregnancy	18
Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19	18
Three-month follow-up of pulmonary embolism in patients with COVID-19	18
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis	18
Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area	18
Tissue factor in COVID-19-associated coagulopathy	18
Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays	18
An overview of thrombotic complications of old and new anticancer drugs	17
The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?	17
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis	17
Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?	17
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis	17
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes	17
Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: A 10-year provincial retrospective cohort study	17
Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges	17
Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials	16
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome	16
COVID-19 associated pulmonary thrombosis	16
Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors	16
How we make an accurate diagnosis of von Willebrand disease	16
Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal	16
Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study	16
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia	16

Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	16
Extracellular vesicles in atrial fibrillation and stroke	16
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy	16
Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature	16
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era	16
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score	16
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study	16
D-dimer as a stand-alone test to rule out deep vein thrombosis	16
Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts	15
Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity	15
Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: Meta-analyses of incidence, temporal trends and potential risk factors	15
Translating the success of prophylaxis in haemophilia to von Willebrand disease	15
Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19	15
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability	15
A nomogram model to predict the venous thromboembolism risk after surgery in patients with gynecological tumors	15
How I treat von Willebrand disease	15
Development and prospective validation of a novel risk score for predicting the risk of lower extremity deep vein thrombosis among multiple trauma patients	15
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes	15
Genetic and epigenetic regulation of cancer coagulome – lessons from heterogeneity of cancer cell populations	15
Hemostatic biomarkers in occult cancer and cancer risk prediction	15
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg	15
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome	15
Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway	15
Coagulation signaling and cancer immunotherapy	15
Patients experience of living with cancer associated thrombosis in France (Le PELICAN)	14
Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state	14
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model	14
Where do we stand with antithrombotic prophylaxis in patients with COVID-19?	14
Thrombosis in hematological malignancies: mechanisms and implications	14
Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor	14
The role of P-selectin in cancer-associated thrombosis and beyond	14
Lifestyle factors and venous thromboembolism in two cohort studies	14
Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study	14
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE	14
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin	14
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada	14
Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents	14
Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic	14
COVID-19 risk perceptions, worries and preventive behaviors in patients with previous pulmonary embolism	14
The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison	14
Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis	14
Immature platelets: a review of the available evidence	14
Short-term exposure to PM2.5 and risk of venous thromboembolism: A case-crossover study	13
Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency	13
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy	13
Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function	13
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance	13
The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention	13
Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer	13
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis	13
Increased levels of platelet-derived microparticles in pulmonary hypertension	13
COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic	13
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study	13
Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients	13
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis	13
Prediction of hypofibrinogenemia and thrombocytopenia at the point of care with the Quantra® QPlus® System	13
Incidence and prevalence of venous thromboembolism in Norway 2010–2017	13
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets	13
Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status	13
Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis	13
Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia	13
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients	12
Neutrophil extracellular traps and cancer-associated thrombosis	12
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome	12
Association between Covid-19 and Pulmonary Embolism (AC-19-PE study)	12
Biomarker association with cardiovascular disease and mortality – The role of fibrinogen. A report from the NHANES study	12
Splanchnic vein thrombosis associated with myeloproliferative neoplasms	12
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies	12
Coagulation factors XI and XII as possible targets for anticoagulant therapy	12
Real-world experience with reversal of dabigatran by idarucizumab	12
A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism	12
NLRP3 inflammasome contributes to endotoxin-induced coagulation	12
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial	12
“Whole life changed” - Experiences of how symptoms derived from acute pulmonary embolism affects life. A qualitative interview study	12
Cancer-associated thrombosis in pediatric patients	12
Pulmonary embolism in coronavirus disease-19 (COVID-19) and use of compression ultrasonography in its optimal management	12
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis	12
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study	12
Cancer-associated non-bacterial thrombotic endocarditis	12
Brain-derived extracellular vesicles mediated coagulopathy, inflammation and apoptosis after sepsis	12
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	12
Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies	12
Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled “Estrogen and thrombosis: A bench to bedside review” (Thrombosis Research 192 (2020) 40–51)	12
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia	12
Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19	12
A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids	11
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry	11
Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoag	11
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection	11
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial	11
Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone	11
Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension	11
Antisense oligonucleotides and nucleic acids generate hypersensitive platelets	11
Multiparameter microfluidics assay of thrombus formation reveals increased sensitivity to contraction and antiplatelet agents at physiological temperature	11
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis	11